安罗替尼联合化疗治疗晚期胆道癌的疗效观察  

Efficacy of anlotinib combined with chemotherapy in the treatment of advanced biliary tract cancer

作　　者：董龙科 杨乔[1] 崔翠花[1] DONG Long-ke;YANG Qiao;CUI Cui-hua(Department of Oncology,Baoji Central Hospital,Baoji 721000,China)

机构地区：[1]陕西省宝鸡市中心医院肿瘤内科,宝鸡721000

出　　处：《中国肿瘤临床与康复》2022年第8期914-917,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的 探讨安罗替尼联合化疗治疗晚期胆道癌的临床疗效。方法 选取2018年8月至2021年8月间宝鸡市中心医院收治的65例晚期胆道癌患者,采用随机数字表法分为研究组33例和对照组32例。研究组患者采用吉西他滨+顺铂+安罗替尼方案化疗治疗,对照组患者采用吉西他滨+顺铂方案治疗,比较两组患者的临床疗效、治疗前后肝功能[总胆红素(TBIL)、直接胆红素(DBIL)、碱性磷酸酶(ALP)]和血清血管内皮生长因子(VEGF)、糖类抗原19-9(CA19-9)及癌胚抗原(CEA)水平。结果 研究组患者客观缓解率为33.3%,疾病控制率为90.9%,高于对照组的21.9%和71.9%,差异均有统计学意义(均P<0.05)。治疗后,两组患者血清TBIL、DBIL和ALP水平均降低,且研究组均低于对照组,差异均有统计学意义(均P<0.05)。治疗后,两组患者血清VEGF、CA19-9和CEA水平均降低,且研究组均低于对照组,差异均有统计学意义(均P<0.05)。研究组患者不良反应发生率为42.4%,高于对照组的25.0%,但差异无统计学意义(P>0.05)。结论 在吉西他滨+顺铂化疗方案基础上联合安罗替尼治疗晚期胆道癌患者,能抑制VEGF表达,降低CA19-9和CEA水平,改善肝功能,提高短期临床疗效,且安全性高。Objective To investigate the clinical efficacy of anlotinib combined with chemotherapy in the treatment of advanced biliary tract cancer. Methods Sixty-five patients with advanced biliary tract cancer who were admitted to Baoji Central Hospital were selected from August 2018 to August 2021. They were randomly divided into an experimental group(33 patients) and a control group(32 patients) using the random number table method. The experimental group received gemcitabine plus cisplatin and anlotinib, and the control group received gemcitabine plus cisplatin. The clinical efficacy, liver function including total bilirubin(TBIL), direct bilirubin(DBIL), alkaline phosphatase(ALP)]and serum vascular endothelial growth factor(VEGF), Carbohydrate antigen 19-9(CA19-9) and carcinoembryonic antigen(CEA) levels were compared between the two groups before and after the treatment. Results The objective response rate(ORR) was 33.3% and disease control rate(DCR) was 90.9%, which was higher than 21.9% and 71.9%, respectively of the control group(all P<0.05). TBIL, DBIL, ALP, VEGF, CA19-9 and CEA levels decreased in both groups and the levels were lower in the experimental group than in the control group(all P<0.05). The adverse reaction rate was 42.4% which was higher than 25.0% of the control group(P<0.05). Conclusion Chemotherapy regimen of gemcitabine plus cisplatin combined with anlotinib in the treatment of advanced biliary tract cancer can significantly inhibit the expression of VEGF, reduce the levels of CA19-9 and CEA, improve liver function and improve short-term clinical efficacy with high safety.

关 键 词：安罗替尼 晚期胆道肿瘤 药物疗法 VEGF CA19-9 CEA 

分 类 号：R735.8[医药卫生—肿瘤]